By Michael Dabaie
Abbott Laboratories (ABT) said it received approval from the U.S. Food and Drug Administration for a new, expanded indication for the company's Infinity Deep Brain Stimulation system.
The company said the indication was expanded to include targeting of an area of the brain called the internal globus pallidus, or GPi. The GPi plays an integral role in the motor function and can be targeted with DBS to improve the symptoms of Parkinson's disease not adequately controlled by medication, the company said.
Abbott shares were up 1.4% in light premarket trading to $92.
Write to Michael Dabaie at firstname.lastname@example.org